Abstract
mTOR signaling pathway (mammalian target of rapamycin) is a major pathway in cell physiology and malignant behavior implicated in cell growth, cell proliferation, cell metabolism, protein synthesis and angiogenesis. Temsirolimus has shown in a randomized phase III trial for patients with poor risk feature of metastatic renal cell carcinoma, a significant gain in overall survival compared to this obtained with alpha interferon (7.3 à 10.9 months; HR: 0.73; P < 0.0069). Everolimus has shown in a randomized phase III trial for patients with metastatic renal cell carcinoma having failed under VEGFR tyrosine kinase inhibitor a significant gain in progression-free survival compared to this obtained with placebo VEGFR (1,8 à 4,6 months; HR: 0.33; P < 0.001). Temsirolimus and everolimus are now part of the reference treatments in renal cell carcinoma. This paper is a review of these two drugs in this setting.
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / metabolism
-
Everolimus
-
Humans
-
Intracellular Signaling Peptides and Proteins / antagonists & inhibitors*
-
Intracellular Signaling Peptides and Proteins / metabolism
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / metabolism
-
PTEN Phosphohydrolase / metabolism
-
Protein Serine-Threonine Kinases / antagonists & inhibitors*
-
Protein Serine-Threonine Kinases / metabolism
-
Proto-Oncogene Proteins c-akt / metabolism
-
Receptors, Vascular Endothelial Growth Factor / metabolism
-
Signal Transduction / drug effects
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
-
TOR Serine-Threonine Kinases
Substances
-
Antineoplastic Agents
-
Intracellular Signaling Peptides and Proteins
-
temsirolimus
-
Everolimus
-
MTOR protein, human
-
Receptors, Vascular Endothelial Growth Factor
-
Protein Serine-Threonine Kinases
-
Proto-Oncogene Proteins c-akt
-
TOR Serine-Threonine Kinases
-
PTEN Phosphohydrolase
-
Sirolimus